News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Thermo Fisher Scientific has licensed rights to gene editing technology for bioproduction applications that it claims targets DNA more precisely and reliably than current approaches.
Glenmark Pharmaceuticals has opened a new cGMP-compliant monoclonal antibody (mAb) manufacturing facility in La Chaux-de-Fonds, Switzerland.
European Provenge contractor PharmaCell BV is looking for new business after completing the acquisition of TiGenix’s biomanufacturing facility in the Netherlands.
Big biopharma biosimilar development strategies vary substantially with Pfizer, Merck and Janssen split on how best to approach the burgeoning market.
The World Health Assembly (WHA) has called on governments and regulators to improve public access to affordable biosimilars, saying the price of medicines can be ‘catastrophic.’
CDMO (contract development and manufacturing organization) PacificGMP has doubled its GMP (good manufacturing practice) production capacity with the addition of a second System 1000 bioreactor platform from GE Healthcare.